Evaluation the effect of 50 and 100 mg doses of Cuminum cyminum essential oil on glycemic indices, insulin resistance and serum inflammatory factors on patients with diabetes type II: A double-blind randomized placebo-controlled clinical trial

Journal of Traditional and Complementary Medicine

Volumn 7, Issue 3, 2017, Pages 332-338

  Jafari, Sahar ^a   Sattari, Roghieh ^a   Ghavamzadeh, Sa'id ^a  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cuminum cyminum; Diabetes type II; Glycemic indices; Green cumin; Inflammatory indices

Indexed keywords

EID: 85008144265     PISSN: None     EISSN: 22254110     Source Type: Journal    
DOI: 10.1016/j.jtcme.2016.08.004     Document Type: Article

References (35)

1. Association AD, Diagnosis and classification of diabetes mellitus. Diabetes Care 33:suppl 1 (2010), S62–S69.
2. Esteghamati, A., Meysamie, A., Khalilzadeh, O., et al. Third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health, 9(1), 2009, 1.
3. Hongyan, Z., Jian, Z., Lei, Z., Jianhui, M., Yongning, S., Yuwu, Z., Characteristics of blood glucose excursions in type 2 diabetes mellitus patients with three different traditional chinese medicine syndromes. J Tradit Chin Med 35:5 (2015), 537–545.
4. Barrett-Connor, E., Diabetes and heart disease. Diabetes Care 26:10 (2003), 2947–2958.
5. Caballero, A.E., Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11:11 (2003), 1278–1289.
6. Farshchi, A., Esteghamati, A., Sari, A.A., et al. The cost of diabetes chronic complications among Iranian people with type 2 diabetes mellitus. J Diabetes & Metab Disord, 13(1), 2014, 42.
7. Abdollahi, M., Farshchi, A., Nikfar, S., Seyedifar, M., Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharm Sci 16:1 (2013), 99–114.
8. Stratton, I.M., Adler, A.I., Neil, H.A.W., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:7258 (2000), 405–412.
9. Association AD, Standards of medical care in diabetes—2013. Diabetes Care, 36(suppl 1), 2013, S11.
10. Chowdhury, T.A., Escudier, V., Poor glycaemic control caused by insulin induced lipohypertrophy. Br Med J, 327(7411), 2003, 383.
11. Matteucci, E., Giampietro, O., Oxidative stress in families of type 1 diabetic patients. Diabetes Care 23:8 (2000), 1182–1186.
12. Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:6 (1972 Jun), 499–502.
13. Kadish, A.H., Litle, R.L., Sternberg, J.C., A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 14:2 (1968), 116–131.
14. Group UPDS, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:9131 (1998), 837–853.
15. Thippeswamy, N., Naidu, K.A., Antioxidant potency of cumin varieties—cumin, black cumin and bitter cumin—on antioxidant systems. Eur Food Res Technol 220:5–6 (2005), 472–476.
16. Patil, S.B., Takalikar, S.S., Joglekar, M.M., Haldavnekar, V.S., Arvindekar, A.U., Insulinotropic and β-cell protective action of cuminaldehyde, cuminol and an inhibitor isolated from Cuminum cyminum in streptozotocin-induced diabetic rats. Br J Nutr 110:8 (2013), 1434–1443.
17. Parthasarathy, V.A., Chempakam, B., Zachariah, T.J., Chemistry of Spices: CABI. 2008.
18. Lee, H.-S., Cuminaldehyde: aldose reductase and α-glucosidase inhibitor derived from Cuminum cyminum L. seeds. J Agric Food Chem 53:7 (2005), 2446–2450.
19. Mugabo, Y., Li, L., Renier, G., The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Curr Diabetes Rev 6:1 (2010), 27–34.
20. Mirza, S., Hossain, M., Mathews, C., et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine 57:1 (2012), 136–142.
21. Kalaivani, P., Saranya, R.B., Ramakrishnan, G., et al. Cuminum cyminum, a dietary spice, attenuates hypertension via endothelial nitric oxide synthase and NO pathway in renovascular hypertensive rats. Clin Exp Hypertens 35:7 (2013), 534–542.
22. Yuanyuan, W., Minghua, J., Lina, Z., et al. Effect of a combination of calorie-restriction therapy and Lingguizhugan decoction on levels of fasting blood lipid and inflammatory cytokines in a high-fat diet induced hyperlipidemia rat model. J Tradit Chin Med 35:2 (2015), 218–221.
23. Andallu, B., Ramya, V., Antihyperglycemic, cholesterol-lowering and HDL-raising effects of cumin (Cuminum cyminum) seeds in type-2 diabetes. J Nat Remedies 7:1 (2007), 142–149.
24. Taghizadeh, M., Memarzadeh, M.R., Asemi, Z., Esmaillzadeh, A., Effect of the Cumin cyminum L. intake on weight loss, metabolic profiles and biomarkers of oxidative stress in overweight subjects: a randomized double-blind placebo-controlled clinical trial. Ann Nutr Metab 66:2–3 (2015), 117–124.
25. Dhandapani, S., Subramanian, V.R., Rajagopal, S., Namasivayam, N., Hypolipidemic effect of Cuminum cyminum L. on alloxan-induced diabetic rats. Pharmacol Res 46:3 (2002), 251–255.
26. Shahnaz, H., Hifza, A., Bushra, K., Khan, J., Lipid studies of Cuminum cyminum fixed oil. Pak J Bot 36:2 (2004), 395–402.
27. Jagtap, A., Patil, P., Antihyperglycemic activity and inhibition of advanced glycation end product formation by Cuminum cyminum in streptozotocin induced diabetic rats. Food Chem Toxicol 48:8 (2010), 2030–2036.
28. Willatgamuwa, S., Platel, K., Saraswathi, G., Srinivasan, K., Antidiabetic influence of dietary cumin seeds (Cuminum cyminum) in streptozotocin induced diabetic rats. Nutr Res 18:1 (1998), 131–142.
29. Mohiti-Ardekani, J., Akbarian, Z., Piri-Ardekani, M.R., Mohiti-Ardekani, A., Comparison of the effects of cuminum cyminuml and sibutramine on weight, serum leptin, glucose and lipids in rat. Iran J Diabetes Obes 4:2 (2012), 74–78.
30. Mohiti Ardekani, J., Akbarian, Z., Nazarian, A., Effects of Cumin (Cuminum cyminum L) oil on serum glucose and lipid levels of rats. SSU J 19:3 (2011), 388–397.
31. Pisprasert, V., Ingram, K.H., Lopez-Davila, M.F., Munoz, A.J., Garvey, W.T., Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 36:4 (2013), 845–853.
32. Asemi, Z., Zare, Z., Shakeri, H., Sabihi, S.-S., Esmaillzadeh, A., Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab 63:1–2 (2013), 1–9.
33. Badr, G., Mahmoud, M.H., Farhat, K., Waly, H., Al-Abdin, O.Z., Rabah, D.M., Maternal supplementation of diabetic mice with thymoquinone protects their offspring from abnormal obesity and diabetes by modulating their lipid profile and free radical production and restoring lymphocyte proliferation via PI3K/AKT signaling. Lipids Health Dis, 12(1), 2013, 1.
34. Borst, S.E., The role of TNF-α in insulin resistance. Endocrine 23:2–3 (2004), 177–182.
35. Yaturu, S., Rains, J., Jain, S.K., Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-α levels in men with type 2 diabetes. Cytokine 44:1 (2008), 168–171.